세계의 저분자 무균 주사제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Small Molecule Sterile Injectable Drugs Market is presumed to reach the market size of nearly USD 304.56 Billion by 2032 from USD 155.05 Billion in 2023 with a CAGR of 7.79% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule sterile injectable drugs. The growth and trends of small molecule sterile injectable drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule sterile injectable drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Antibiotics
• Chemotherapy Agents
• Skeletal Muscle Relaxants
• Anaesthetics
• Anticoagulants
• Anticonvulsants
• Antivirals
• Other

By Product Type

• Branded
• Generics

By Route Of Administration

• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)

By Application

• Oncology
• Infectious Diseases
• Diabetes
• Musculoskeletal
• Autoimmune Disorders
• Cardiovascular Diseases
• Cns Disorders
• Other

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Sterile Injectable Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Sterile Injectable Drugs market include AbbVie Inc., Amgen Inc., AstraZeneca Plc., BioCryst Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Fresenius Kabi USA, Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. SMALL MOLECULE STERILE INJECTABLE DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Product Type
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Application
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY DRUG TYPE

• 5.1. Overview By Drug Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Drug Type
• 5.4. Antibiotics Historic and Forecast Sales By Regions
• 5.5. Chemotherapy Agents Historic and Forecast Sales By Regions
• 5.6. Skeletal Muscle Relaxants Historic and Forecast Sales By Regions
• 5.7. Anaesthetics Historic and Forecast Sales By Regions
• 5.8. Anticoagulants Historic and Forecast Sales By Regions
• 5.9. Anticonvulsants Historic and Forecast Sales By Regions
• 5.10. Antivirals Historic and Forecast Sales By Regions
• 5.11. Other Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY PRODUCT TYPE

• 6.1. Overview By Product Type
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Product Type
• 6.4. Branded Historic and Forecast Sales By Regions
• 6.5. Generics Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Route of Administration
• 7.4. Intravenous (IV) Historic and Forecast Sales By Regions
• 7.5. Intramuscular (IM) Historic and Forecast Sales By Regions
• 7.6. Subcutaneous (SC) Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY APPLICATION

• 8.1. Overview By Application
• 8.2. Historical and Forecast Data
• 8.3. Analysis By Application
• 8.4. Oncology Historic and Forecast Sales By Regions
• 8.5. Infectious Diseases Historic and Forecast Sales By Regions
• 8.6. Diabetes Historic and Forecast Sales By Regions
• 8.7. Musculoskeletal Historic and Forecast Sales By Regions
• 8.8. Autoimmune Disorders Historic and Forecast Sales By Regions
• 8.9. Cardiovascular Diseases Historic and Forecast Sales By Regions
• 8.10. CNS Disorders Historic and Forecast Sales By Regions
• 8.11. Other Historic and Forecast Sales By Regions

9. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1. Overview By Distribution Channel
• 9.2. Historical and Forecast Data
• 9.3. Analysis By Distribution Channel
• 9.4. Hospital Pharmacies Historic and Forecast Sales By Regions
• 9.5. Retail Pharmacies Historic and Forecast Sales By Regions
• 9.6. Online Pharmacies Historic and Forecast Sales By Regions

10. GLOBAL SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE STERILE INJECTABLE DRUGS COMPANIES

• 11.1. Small Molecule Sterile Injectable Drugs Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF SMALL MOLECULE STERILE INJECTABLE DRUGS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. AbbVie Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Amgen Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. AstraZeneca Plc.
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. BioCryst Pharmaceuticals Inc.
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Bristol-Myers Squibb Company
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Eisai Co. Ltd.
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Eli Lilly And Company
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Fresenius Kabi USA
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. Gilead Sciences Inc.
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Merck KGaA
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. Novartis AG
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Pfizer Inc.
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments
• 12.15. Sanofi
  • 12.15.1 Company Overview
  • 12.15.2 Company Revenue
  • 12.15.3 Products
  • 12.15.4 Recent Developments
• 12.16. Sun Pharmaceutical Industries Ltd.
  • 12.16.1 Company Overview
  • 12.16.2 Company Revenue
  • 12.16.3 Products
  • 12.16.4 Recent Developments
• 12.17. Teva Pharmaceutical Industries Ltd.
  • 12.17.1 Company Overview
  • 12.17.2 Company Revenue
  • 12.17.3 Products
  • 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies